124 related articles for article (PubMed ID: 10696236)
1. Inhibition of solid tumor growth by Fas ligand-expressing myoblasts.
Springer ML; Kraft PE; Blau HM
Somat Cell Mol Genet; 1998 Sep; 24(5):281-9. PubMed ID: 10696236
[TBL] [Abstract][Full Text] [Related]
2. Death of solid tumor cells induced by Fas ligand expressing primary myoblasts.
Hofmann A; Blau HM
Somat Cell Mol Genet; 1997 Jul; 23(4):249-57. PubMed ID: 9542527
[TBL] [Abstract][Full Text] [Related]
3. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells.
Shimizu M; Fontana A; Takeda Y; Yagita H; Yoshimoto T; Matsuzawa A
J Immunol; 1999 Jun; 162(12):7350-7. PubMed ID: 10358186
[TBL] [Abstract][Full Text] [Related]
4. Cutting edge: a novel role for Fas ligand in facilitating antigen acquisition by dendritic cells.
Tada Y; O-Wang J; Takiguchi Y; Tatsumi K; Kuriyama T; Okada S; Tokuhisa T; Sakiyama S; Tagawa M
J Immunol; 2002 Sep; 169(5):2241-5. PubMed ID: 12193688
[TBL] [Abstract][Full Text] [Related]
5. Membrane Fas ligand activates innate immunity and terminates ocular immune privilege.
Gregory MS; Repp AC; Holhbaum AM; Saff RR; Marshak-Rothstein A; Ksander BR
J Immunol; 2002 Sep; 169(5):2727-35. PubMed ID: 12193747
[TBL] [Abstract][Full Text] [Related]
6. Growth of FasL-bearing tumor cells in syngeneic murine host induces apoptosis and toxicity in Fas(+) organs.
Zeytun A; Nagarkatti M; Nagarkatti PS
Blood; 2000 Mar; 95(6):2111-7. PubMed ID: 10706882
[TBL] [Abstract][Full Text] [Related]
7. Fulminant hepatitis by Fas-ligand expression in MRL-lpr/lpr mice grafted with Fas-positive livers and wild-type mice with Fas-mutant livers.
Li XK; Fujino M; Sugioka A; Morita M; Okuyama T; Guo L; Funeshima N; Kimura H; Enosawa S; Amemiya H; Suzuki S
Transplantation; 2001 Feb; 71(4):503-8. PubMed ID: 11258428
[TBL] [Abstract][Full Text] [Related]
8. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively.
Hashimoto W; Osaki T; Okamura H; Robbins PD; Kurimoto M; Nagata S; Lotze MT; Tahara H
J Immunol; 1999 Jul; 163(2):583-9. PubMed ID: 10395644
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effects are produced by forced expression of membrane-bound but not soluble Fas ligand in murine lung carcinoma cells.
Tada Y; O-Wang J; Seimiya M; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
Anticancer Res; 2002; 22(2A):831-6. PubMed ID: 12014659
[TBL] [Abstract][Full Text] [Related]
10. Fas ligand engagement of resident peritoneal macrophages in vivo induces apoptosis and the production of neutrophil chemotactic factors.
Hohlbaum AM; Gregory MS; Ju ST; Marshak-Rothstein A
J Immunol; 2001 Dec; 167(11):6217-24. PubMed ID: 11714783
[TBL] [Abstract][Full Text] [Related]
11. Fas ligand-transfected myoblasts and islet cell transplantation.
Turvey SE; Gonzalez-Nicolini V; Kingsley CI; Larregina AT; Morris PJ; Castro MG; Lowenstein PR; Wood KJ
Transplantation; 2000 May; 69(9):1972-6. PubMed ID: 10830245
[TBL] [Abstract][Full Text] [Related]
12. Fas ligand on tumor cells mediates inactivation of neutrophils.
Chen YL; Chen SH; Wang JY; Yang BC
J Immunol; 2003 Aug; 171(3):1183-91. PubMed ID: 12874204
[TBL] [Abstract][Full Text] [Related]
13. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice.
Lau HT; Yu M; Fontana A; Stoeckert CJ
Science; 1996 Jul; 273(5271):109-12. PubMed ID: 8658177
[TBL] [Abstract][Full Text] [Related]
14. Direct in vivo transfection of antisense Fas-ligand reduces tumor growth and invasion.
Nyhus JK; Wolford C; Feng L; Barbera-Guillem E
Gene Ther; 2001 Feb; 8(3):209-14. PubMed ID: 11313792
[TBL] [Abstract][Full Text] [Related]
15. Fas/Apo-1 (CD95)-mediated apoptosis of neutrophils with Fas ligand (CD95L)-expressing tumors is crucial for induction of inflammation by neutrophilic polymorphonuclear leukocytes associated with antitumor immunity.
Shimizu M; Fontana A; Takeda Y; Yoshimoto T; Tsubura A; Matsuzawa A
Cell Immunol; 2001 Jan; 207(1):41-8. PubMed ID: 11161452
[TBL] [Abstract][Full Text] [Related]
16. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit T cell-mediated cytotoxicity by inhibiting Fas ligand expression.
Delgado M; Ganea D
J Immunol; 2000 Jul; 165(1):114-23. PubMed ID: 10861043
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of autoimmune diabetes by Fas ligand: the paradox is solved.
Kim S; Kim KA; Hwang DY; Lee TH; Kayagaki N; Yagita H; Lee MS
J Immunol; 2000 Mar; 164(6):2931-6. PubMed ID: 10706679
[TBL] [Abstract][Full Text] [Related]
18. Fas-mediated cytotoxicity is not required for rejection of murine nonvascularized heterotopic cardiac allografts.
Djamali A; Odorico JS
Transplantation; 1998 Dec; 66(12):1793-801. PubMed ID: 9884278
[TBL] [Abstract][Full Text] [Related]
19. p53 promotes selection for Fas-mediated apoptotic resistance.
Maecker HL; Koumenis C; Giaccia AJ
Cancer Res; 2000 Aug; 60(16):4638-44. PubMed ID: 10969818
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival.
Min WP; Gorczynski R; Huang XY; Kushida M; Kim P; Obataki M; Lei J; Suri RM; Cattral MS
J Immunol; 2000 Jan; 164(1):161-7. PubMed ID: 10605007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
